MJH Life Sciences has acquired BPD Healthcare, expanding strategic capabilities for hospitals, healthcare innovators and health systems.

The move builds on MJH’s history of collaborating with health systems and hospitals through its strategic alliance partnership (SAP) programme to support improved patient care.

BPD and MJH together offer a blend of reach and strategic capabilities to healthcare stakeholders and brands.

MJH’s collaborations with researchers, clinicians and healthcare organisations pair with BPD’s expertise in assisting these organisations grow, engage and navigate the evolving challenges of patient care.

This deal aims to integrate BPD’s data-driven strategies with MJH’s healthcare content, fostering smarter innovation across the sector for improved patient outcomes.

MJH Life Sciences chairman and CEO Michael Hennessy Jr said: “This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation.

“BPD shares our unwavering belief that when innovation meets communication, healthcare moves forward. Together, we’re not just connecting information, we’re accelerating how health systems, hospitals, and organisations reach patients and redefine what state-of-the-art care looks and feels like."

BPD partners with health systems and academic medical centres in the US, delivering integrated solutions in business consulting, communications, marketing, and branding.

The company’s services are AI-infused, technology-enabled, and supported by a data platform, addressing areas such as patient acquisition, market assessments, reputation management, physician referrals, team engagement, payor negotiations, and talent recruitment.

BPD CEO Jason Brown said: “Healthcare is changing faster than ever, and the organisations that thrive will be the ones that connect meaning with action.

“Joining MJH Life Sciences allows BPD to bring that connection to life on a much larger scale. Together, we can help our clients not just grow their brands but strengthen and innovate the industry to better care for patients and communities.”

BPD will maintain its operations as an independent wholly owned subsidiary of MJH Life Sciences.

This collaboration aims to further strengthen BPD's capacity to provide integrated, data-driven solutions for its clients.